pharma · Duchenne muscular dystrophy (DMD) · JAK2V617F-positive high-risk Polycythemia Vera
ITALFARMACO S.P.A
Italfarmaco S.p.A.
Italfarmaco S.p.A is a pharma organization headquartered in MILANO, IT. Primary therapeutic focus areas include Duchenne muscular dystrophy (DMD), JAK2V617F-positive high-risk Polycythemia Vera, Chronic myeloproliferativ
Cinisello Balsamo, IT HQ
1938 Founded
629 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Cinisello Balsamo, IT
- Founded
- 1938
- Employees
- 629
- Programs
- 7
- Drugs
- 17
- Patents
- 0
ITF2357-60
Phase 1 · other · Participants with normal hepatic function, Participants with moderate HI, Participants with mild HI
ITF2357-60 for Participants with normal hepatic function, Participants with moderate HI, Participants with mild HI is a Phase 1 program (other) at Italfarmaco S.p.A. with 1 ClinicalTrials.gov record(s).
Internal code ITF2357-60
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Italfarmaco S.p.A.
- Phase
- Phase 1
- Modality
- other
- Indication
- Participants with normal hepatic function, Participants with moderate HI, Participants with mild HI
- Status
- active
- Trials
- 1